EUCTR2011-004208-39-IT进行中（未招募）1 期
Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to fiRst pulmonary exacErbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis. - RESPIRE 1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Age >18 years; ? Proven and documented diagnosis of non-CF idiopathic or postinfectious BE by both: ? HRCT scan including 2 or more lobes and dilated airways compatible with BE at initial diagnosis; and ? Positive culture from an adequate sputum sample for Pseudomonas aeruginosa, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Streptococcus pneumoniae, Stenotrophomonas maltophilia or Burkholderia cepacia at screening and with history >=2 documented exacerbations in the past 12 months; ? Stable pulmonary status as indicated by FEV1 (percent of predicted) >=30% and <90% (post-bronchodilator, if used as standard of treatment); ? Stable regimen of standard treatment with: - Bronchodilators, anticholinergics, inhaled corticosteroids, or mucolytics, if used as chronic treatment for BE, at least for the past 4 weeks prior to screening; Subjects on maintenance therapy with low-dose systemic corticosteroids should be receiving <=10 mg/day prednisolone equivalent at least for the past 4 weeks before the screening visit; and/or - Macrolides if used as chronic treatment for BE for at least 6 months prior to screening; ? Sputum production on the majority of days; ? Ability to follow the inhaler device instructions; ? Ability to complete questionnaires; ? Written informed consent; ? Negative urine pregnancy test result for women of childbearing potential before first dose of study drug; ? Women of childbearing potential and men must agree to use adequate contraception when sexually active. This applies from the time of signing of the informed consent form (ICF) until 3 months after the last study drug administration. Adequate methods of contraception include vasectomy, or condom use, diaphragm with spermicidal gel, coil (intrauterine device), surgical sterilization, or oral contraceptives.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •? FEV1 <30% or >=90% predicted (post-bronchodilator); ? Active allergic bronchopulmonary aspergillosis (ABPA); ? Active and actively-treated non-tuberculosis mycobacterial (NTM) infection or tuberculosis; ? Diagnosis of common variable immunodeficiency (CVID); ? Recent significant hemoptysis (>=300 mL or requiring blood transfusion) in the preceding 4 weeks before screening (and during the screening period); ? Primary diagnosis of COPD; ? Known CF and / or documented chronic bronchial asthma; ? Administration of any investigational drug within 4 weeks before screening;? Medical history of allergies to quinolones or fluoroquinolones; ? Women who are pregnant, lactating, or in whom pregnancy cannot be excluded; ? History of tendon disease and other disorders related to quinolone treatment; ? History of myasthenia gravis; ? Concomitant administration of tizanidine while on study drug; ? Systemic or inhaled antibiotic treatment for any indication within 4 weeks prior to the administration of study drug;except for chronic macrolide use ? Systemic corticosteroids at >10 mg/day prednisolone equivalent for >14 days within 4 weeks prior to the administration of study drug;? Previous assignment to treatment in this study (randomized in Study 15625).
研究者
相似试验
进行中（未招募）
1 期
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non–CF BE)non-CF bronchiectasisMedDRA version: 19.0Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-004659-19-DEBayer AG492
进行中（未招募）
不适用
Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH). - PATENT-1 StudyPulmonary Arterial Hypertension (PAH)MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-003482-68-DKBayer HealthCare AG, D-51368 Leverkusen462
进行中（未招募）
2 期
Study of efficacy and safety of NaPPS in patients with knee osteoarthritisknee osteoarthritisJPRN-jRCT2071210131Matsumoto Tadashi90
进行中（未招募）
不适用
Evaluation of different oral doses and regimens of GLPG0634 given for 24 weeks in patients with active rheumatoid arthritis and an insufficient response to methotrexate alonemoderately to severely active rheumatoid arthritisMedDRA version: 17.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-003635-31-ATGalapagos NV595
进行中（未招募）
不适用
Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosisMedDRA version: 9.1Level: PTClassification code 10011763Term: Cystic fibrosis lungCystic fibrosisEUCTR2008-008314-40-DEBayer HealthCare AG276